X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15304) 15304
Book Review (1622) 1622
Publication (1206) 1206
Dissertation (38) 38
Conference Proceeding (37) 37
Book Chapter (36) 36
Government Document (8) 8
Magazine Article (5) 5
Web Resource (4) 4
Data Set (3) 3
Book / eBook (2) 2
Paper (2) 2
Newspaper Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (11563) 11563
cyclooxygenase-2 (9890) 9890
humans (6917) 6917
animals (5950) 5950
male (4053) 4053
inflammation (3404) 3404
female (3241) 3241
mice (3124) 3124
expression (2889) 2889
oncology (2763) 2763
cyclooxygenase 2 - metabolism (2641) 2641
pharmacology & pharmacy (2470) 2470
rats (2318) 2318
cox-2 inhibitors (2312) 2312
cancer (2277) 2277
nonsteroidal antiinflammatory drugs (2227) 2227
apoptosis (2162) 2162
celecoxib (2155) 2155
cox-2 (1910) 1910
biochemistry & molecular biology (1774) 1774
cyclooxygenase-2 expression (1745) 1745
cyclooxygenase 2 (1743) 1743
inhibition (1577) 1577
middle aged (1548) 1548
cell biology (1509) 1509
nitric-oxide synthase (1420) 1420
prostaglandin endoperoxide synthase (1412) 1412
activation (1396) 1396
gene expression (1386) 1386
cells (1351) 1351
analysis (1324) 1324
cyclooxygenase 2 - genetics (1319) 1319
rodents (1311) 1311
aged (1281) 1281
proteins (1278) 1278
cyclooxygenase-2 inhibitor (1263) 1263
adult (1252) 1252
nf-kappa-b (1247) 1247
cyclooxygenase inhibitors - pharmacology (1212) 1212
cell line, tumor (1206) 1206
cytokines (1118) 1118
membrane proteins (1118) 1118
nitric oxide (1115) 1115
research (1096) 1096
signal transduction (1062) 1062
dose-response relationship, drug (1050) 1050
cyclooxygenase 2 inhibitors - pharmacology (1026) 1026
prostaglandins (1025) 1025
immunohistochemistry (1005) 1005
sulfonamides - pharmacology (998) 998
cyclooxygenase-2 inhibitors (993) 993
immunology (982) 982
gene-expression (981) 981
chemistry, medicinal (971) 971
anti-inflammatory agents, non-steroidal - pharmacology (953) 953
enzymes (930) 930
oxidative stress (908) 908
prostaglandin e2 (906) 906
cells, cultured (898) 898
prostaglandin-endoperoxide synthases - metabolism (891) 891
in-vitro (885) 885
prostaglandin e-2 (884) 884
research article (884) 884
kinases (872) 872
cyclooxygenase 2 inhibitors (863) 863
macrophages (854) 854
phosphorylation (842) 842
anti-inflammatory agents, non-steroidal - therapeutic use (841) 841
angiogenesis (837) 837
disease models, animal (834) 834
medicine (828) 828
cell line (826) 826
apoptosis - drug effects (820) 820
dinoprostone - metabolism (809) 809
health aspects (792) 792
medicine, research & experimental (774) 774
care and treatment (767) 767
neurosciences (765) 765
rheumatoid-arthritis (765) 765
prevention (760) 760
tumors (758) 758
inhibitors (753) 753
colorectal-cancer (752) 752
rats, sprague-dawley (750) 750
growth (744) 744
nonsteroidal anti-inflammatory drugs (743) 743
aspirin (736) 736
article (732) 732
multidisciplinary sciences (730) 730
blotting, western (722) 722
risk factors (712) 712
up-regulation (693) 693
risk (692) 692
cyclooxygenase (680) 680
gastroenterology & hepatology (671) 671
physiological aspects (663) 663
physiology (662) 662
studies (659) 659
cell proliferation - drug effects (657) 657
nf-kappa b - metabolism (657) 657
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15186) 15186
German (48) 48
Japanese (45) 45
French (43) 43
Korean (22) 22
Chinese (21) 21
Spanish (20) 20
Russian (12) 12
Portuguese (9) 9
Polish (6) 6
Croatian (2) 2
Persian (2) 2
Turkish (2) 2
Czech (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9573, pp. 1621 - 1626
Summary Background Guidelines on pain management recommend that patients at risk of ulcers receive either a cyclo-oxygenase (COX 2) inhibitor or a... 
Internal Medicine | ESOMEPRAZOLE | MEDICINE, GENERAL & INTERNAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NSAID | CYCLOOXYGENASE-2 INHIBITORS | ARTHRITIS PATIENTS | NAPROXEN | COMPLICATIONS | HELICOBACTER-PYLORI | PEPTIC-ULCER | CELECOXIB | Pyrazoles - therapeutic use | Humans | Esomeprazole - adverse effects | Male | Secondary Prevention | Osteoarthritis - drug therapy | Esomeprazole - therapeutic use | Peptic Ulcer Hemorrhage - prevention & control | Female | Drug Therapy, Combination | Pyrazoles - adverse effects | Anti-Ulcer Agents - therapeutic use | Double-Blind Method | Proton Pump Inhibitors | Risk Factors | Anti-Ulcer Agents - adverse effects | Peptic Ulcer Hemorrhage - chemically induced | Treatment Outcome | Celecoxib | Peptic Ulcer Hemorrhage - therapy | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Sulfonamides - adverse effects | Aged | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - therapeutic use | Prevention | Complications and side effects | COX-2 inhibitors | Relapse | Gastrointestinal bleeding | Peptic ulcer | Proton pump inhibitors | Dosage and administration | Drug therapy | Diseases | Drugs | Medical research | Physical examinations | Hospitals | Analgesics | Ulcers | Terminal illnesses | Clinical trials | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 2016, Volume 14, Issue 6, pp. 809 - 815.e1
Journal Article
Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, 10/2017, Volume 26, Issue 10, pp. 1141 - 1148
PurposeTo assess the risk of gastrointestinal perforation, ulcers, or bleeding (PUB) associated with the use of conventional nonsteroidal anti-inflammatory... 
proton pump inhibitors | bleeding | gastrointestinal toxicity | perforation | selective COX‐2 inhibitors | ulcers | conventional NSAIDs | selective COX-2 inhibitors | RHEUMATOID-ARTHRITIS | CARDIOVASCULAR EVENTS | NONSELECTIVE NSAIDS | CELECOXIB | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | CONTROLLED TRIALS | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | HIGH-RISK | CYCLOOXYGENASE-2 INHIBITORS | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | OSTEOARTHRITIS | Age Factors | Humans | Middle Aged | Peptic Ulcer - prevention & control | Male | Peptic Ulcer - epidemiology | Gastrointestinal Hemorrhage - epidemiology | Case-Control Studies | Cyclooxygenase 2 Inhibitors - adverse effects | Peptic Ulcer Perforation - epidemiology | Pain - drug therapy | Pain Management - adverse effects | Aged, 80 and over | Female | Odds Ratio | Peptic Ulcer - complications | Risk Factors | Pain Management - methods | Proton Pump Inhibitors - therapeutic use | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Peptic Ulcer Perforation - prevention & control | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Aged | Peptic Ulcer - chemically induced | Peptic Ulcer Perforation - etiology | COX-2 inhibitors | Proton pump inhibitors | Nonsteroidal anti-inflammatory drugs | Drugs | Antiinflammatory agents | Control methods | Adjustment | Toxicity | Perforation | Pharmacology | Inflammation | Regression analysis | Patients | Risk factors | Bleeding | Nonsteroidal antiinflammatory drugs | Confidence intervals | Inhibitors | Ulcers | Cyclooxygenase-2 | Health risk assessment | Index Medicus | Original Report | Original Reports
Journal Article
Journal Article
Oncology Reports, ISSN 1021-335X, 11/2017, Volume 38, Issue 5, pp. 2657 - 2666
Chemotherapy is one of the most effective non-surgical treatments for various types of tumor. Identifying different combinations of antitumor agents that can... 
PGE2 | COX-2 | celecoxib | PTEN | AKT | HDAC6 inhibitor | HDAC | Celecoxib | CANCER CELLS | ACETYLATION | PANCREATIC-CANCER | RECEPTOR | BREAST-CANCER | INVASION | ONCOLOGY | CYCLOOXYGENASE-2 INHIBITORS | MALIGNANCIES | EXPRESSION | HISTONE DEACETYLASE | Celecoxib - administration & dosage | Humans | Transcriptional Activation - drug effects | Histone Deacetylase Inhibitors - administration & dosage | Indoles - administration & dosage | Glioblastoma - genetics | Hydroxamic Acids - administration & dosage | Glioblastoma - metabolism | Indoles - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Hydroxamic Acids - pharmacology | Cell Survival - drug effects | PTEN Phosphohydrolase - genetics | Cyclooxygenase 2 Inhibitors - pharmacology | Cyclooxygenase 2 Inhibitors - administration & dosage | PTEN Phosphohydrolase - metabolism | Celecoxib - pharmacology | Drug Synergism | Xenograft Model Antitumor Assays | Cell Movement - drug effects | Animals | Anilides - administration & dosage | Anilides - pharmacology | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Cell Proliferation - drug effects | Mice | Mutation | Glioblastoma - drug therapy | Care and treatment | Cellular signal transduction | Enzyme inhibitors | Health aspects | Methods | Cancer | Immunoglobulins | Phosphorylation | Lung cancer | Breast cancer | Kinases | Cancer therapies | Proteins | Cell growth | Chemotherapy | Protein expression | Tumors | Apoptosis | Index Medicus
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 2012, Volume 47, Issue 1, pp. 111 - 124
Balanced modulation of several targets is one of the current strategies for the treatment of multi-factorial diseases. Based on the knowledge of inflammation... 
Multi-target drugs | Benzo/benzisothiazolidinones | Inflammation | Lipoxygenase inhibitors | COX-1/2 inhibitors | Fragment-based drug design | CHEMISTRY, MEDICINAL | CYCLOOXYGENASE-2 | MECHANISM | CRYSTAL-STRUCTURE | LIPOXYGENASES | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | COX-2 INHIBITORS | DUAL INHIBITORS | DERIVATIVES | ANTIMICROBIAL ACTIVITY | LIGAND DESIGN | Thiazolidines - chemical synthesis | Thiazolidines - metabolism | Male | Structure-Activity Relationship | Anti-Inflammatory Agents - metabolism | Lipoxygenase - metabolism | Lipoxygenase Inhibitors - chemical synthesis | Lipoxygenase Inhibitors - chemistry | Drug Design | Cyclooxygenase 1 - chemistry | Female | Thiazolidines - pharmacology | Thiazolidines - chemistry | Catalytic Domain | Cyclooxygenase Inhibitors - metabolism | Anti-Inflammatory Agents - pharmacology | Cyclooxygenase 2 - chemistry | Models, Molecular | Cyclooxygenase Inhibitors - chemistry | Edema - drug therapy | Lipoxygenase - chemistry | Cyclooxygenase Inhibitors - pharmacology | Animals | Anti-Inflammatory Agents - chemistry | Cyclooxygenase 2 - metabolism | Cyclooxygenase Inhibitors - chemical synthesis | Anti-Inflammatory Agents - chemical synthesis | Lipoxygenase Inhibitors - metabolism | Mice | Cyclooxygenase 1 - metabolism | Edema - chemically induced | Lipoxygenase Inhibitors - pharmacology | COX-2 inhibitors | Enzymes | Index Medicus
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 2008, Volume 75, Issue 2, pp. 484 - 493
Aldo-keto reductase (AKR) 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase) regulates ligand access to steroid hormone and prostaglandin... 
Prostaglandin metabolism | Inhibitor design | Steroid hormone metabolism | Cancer treatment | NSAIDs | Chemoprevention | cancer treatment | ANDROGEN RECEPTOR | SIGNALING PATHWAYS | INCREASED EXPRESSION | CRYSTAL-STRUCTURE | prostaglandin metabolism | 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J | PROLIFERATOR-ACTIVATED RECEPTOR | 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE | chemoprevention | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | ACID-BINDING PROTEIN | CYCLOOXYGENASE-2 INHIBITORS | inhibitor design | PHARMACOLOGY & PHARMACY | steroid hormone metabolism | Indomethacin - analogs & derivatives | Oxidation-Reduction | Humans | Enzyme Inhibitors - pharmacology | Hydroxyprostaglandin Dehydrogenases - metabolism | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | 3-Hydroxysteroid Dehydrogenases - antagonists & inhibitors | Hydroxyprostaglandin Dehydrogenases - antagonists & inhibitors | Melatonin - analogs & derivatives | Aldo-Keto Reductase Family 1 Member C3 | 3-Hydroxysteroid Dehydrogenases - metabolism | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Catalysis | Neoplasms, Hormone-Dependent - drug therapy | Melatonin - pharmacology | Phenanthrenes - metabolism | Dihydrotestosterone - metabolism | Enzymes | Care and treatment | Synthetic prostaglandins F | Crystals | Hormones | Organic acids | Heterocyclic compounds | Physiological aspects | Glycols | Hormones, Sex | Indomethacin | Structure | Cancer | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2015, Volume 10, Issue 9, pp. e0139212 - e0139212
Background Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a... 
IBUPROFEN | ENZYME | COX-2 | OXYGENATION | ENDOCANNABINOIDS | MULTIDISCIPLINARY SCIENCES | ANANDAMIDE | INDOMETHACIN | FLURBIPROFEN | LINEAR-MODELS | ANTIINFLAMMATORY DRUGS | Endocannabinoids - metabolism | Stereoisomerism | Humans | Brain - enzymology | Male | Arachidonic Acids - metabolism | Isoenzymes - metabolism | Benzamides - pharmacology | Carbamates - pharmacology | Amides - pharmacology | Amidohydrolases - metabolism | Amidohydrolases - antagonists & inhibitors | Polyunsaturated Alkamides - metabolism | Cyclooxygenase Inhibitors - pharmacology | Hydrolysis | Animals | Arachidonic Acid - pharmacology | Cyclooxygenase 2 - metabolism | Lipid Metabolism - drug effects | Lipopolysaccharides - pharmacology | Amides - chemistry | Ionomycin - pharmacology | RAW 264.7 Cells | Mice | Cyclooxygenase 1 - metabolism | Flurbiprofen - pharmacology | Interferon-gamma - pharmacology | Prostaglandins - metabolism | Brain | COX-2 inhibitors | Neurosciences | Lipids | Enantiomers | Arachidonic acid | Macrophages | Prostaglandin endoperoxide synthase | Pain | 2-Arachidonylglycerol | Rodents | Inhibition | Nonsteroidal anti-inflammatory drugs | Flurbiprofen | Functional foods & nutraceuticals | Fatty-acid amide hydrolase | Enzymes | Hydrolase | Substrate inhibition | Pharmacology | Prostaglandin D2 | Fatty acids | Substrates | Anandamide | Environmental science | Inhibitors | Cyclooxygenase-1 | Interferon | Cyclooxygenase-2 | Oxygenation | Pharmaceuticals | Index Medicus | Basic Medicine | Farmakologi och toxikologi | Medical and Health Sciences | Pharmacology and Toxicology | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Journal of Immunology, ISSN 0022-1767, 06/2000, Volume 164, Issue 12, pp. 6509 - 6519
Resveratrol (trans-3,4',5-trihydroxystilbene), a polyphenolic phytoalexin found in grapes, fruits, and root extracts of the weed Polygonum cuspidatum, exhibits... 
SIGNAL-TRANSDUCTION | TUMOR-NECROSIS-FACTOR | NITRIC-OXIDE SYNTHASE | C-JUN KINASE | GENE-EXPRESSION | CYCLOOXYGENASE-2 EXPRESSION | DEPENDENT APOPTOSIS | RED WINE | IMMUNOLOGY | CORONARY HEART-DISEASE | FACTOR-ALPHA | Okadaic Acid - pharmacology | Reactive Oxygen Species - metabolism | Tetradecanoylphorbol Acetate - pharmacology | Apoptosis - drug effects | Humans | Transcription Factor RelA | NF-kappa B - metabolism | Lipopolysaccharides - antagonists & inhibitors | Stilbenes - pharmacology | Transcription Factor AP-1 - metabolism | DNA-Binding Proteins - metabolism | Reactive Oxygen Species - physiology | Cell Nucleus - metabolism | Lipid Peroxidation - drug effects | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Resveratrol | JNK Mitogen-Activated Protein Kinases | Biological Transport - drug effects | Phosphorylation - drug effects | Cytotoxicity, Immunologic - drug effects | Immunosuppressive Agents - pharmacology | Cell Line | NF-KappaB Inhibitor alpha | NF-kappa B - antagonists & inhibitors | DNA-Binding Proteins - antagonists & inhibitors | NF-kappa B p50 Subunit | Okadaic Acid - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Hydrogen Peroxide - pharmacology | I-kappa B Proteins | Ceramides - antagonists & inhibitors | Caspase Inhibitors | Ceramides - pharmacology | Gene Expression Regulation - drug effects | Tumor Necrosis Factor-alpha - pharmacology | Transcription Factor AP-1 - antagonists & inhibitors | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Lipopolysaccharides - pharmacology | Genes, Reporter - drug effects | Cell Nucleus - drug effects | Hydrogen Peroxide - antagonists & inhibitors | MAP Kinase Kinase Kinase 1 | Tumor Necrosis Factor-alpha - antagonists & inhibitors | resveratrol | reactive oxygen intermediates | NF-^KB protein | Index Medicus | Abridged Index Medicus
Journal Article
Gut, ISSN 0017-5749, 06/2012, Volume 61, Issue 6, pp. 812 - 818
ObjectiveHelicobacter pylori infection and overexpression of cyclo-oxygenase-2 (COX-2) are associated with gastric cancer and its precursors. To evaluate the... 
NONSTEROIDAL ANTIINFLAMMATORY DRUGS | HIGH-RISK | DOUBLE-BLIND | RANDOMIZED-TRIAL | CHEMOPREVENTION | GASTROENTEROLOGY & HEPATOLOGY | CLINICAL-PRACTICE | CANCER | CELECOXIB | CYCLOOXYGENASE-2 INHIBITOR | CHINESE POPULATION | Precancerous Conditions - etiology | Pyrazoles - therapeutic use | Humans | Middle Aged | Helicobacter Infections - complications | Male | Stomach Neoplasms - pathology | Anti-Bacterial Agents - therapeutic use | Helicobacter pylori | Helicobacter Infections - drug therapy | Cyclooxygenase 2 Inhibitors - therapeutic use | Clarithromycin - administration & dosage | Adult | Female | Precancerous Conditions - pathology | Amoxicillin - administration & dosage | Drug Therapy, Combination | Stomach Neoplasms - etiology | Omeprazole - therapeutic use | Stomach - pathology | Double-Blind Method | Omeprazole - administration & dosage | Clarithromycin - therapeutic use | Celecoxib | Sulfonamides - therapeutic use | Stomach Neoplasms - prevention & control | Amoxicillin - therapeutic use | Precancerous Conditions - prevention & control | Anti-Bacterial Agents - administration & dosage | COX-2 inhibitors | Helicobacter infections | Dosage and administration | Research | Drug therapy | Precancerous conditions | Studies | Pathology | Antibiotics | Biopsy | Quality | Population | Endoscopy | Stomach cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article